Medical Device

- The GI Genius Module Assists Physicians in Detecting Pre-Cancerous Growths; Potentially Addressing 19 Million Colonoscopies Annually

- Transformative AI Colorectal Cancer Prevention Platform Expands Medtronic Capabilities in Medical Technology Data Analytics and Insights

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) granted de novo clearance for GI Genius™ intelligent endoscopy module in the United States . The GI Genius module is the first and only commercially available computer-aided detection (CADe) system using artificial intelligence (AI) to identify colorectal polyps. The module, compatible with any colonoscope video, provides physicians with a powerful new solution in the fight against colorectal cancer — the third most common form of cancer globally with 1.8 million new cases in 2018. 1

"More than 19 million screening colonoscopies are performed in the United States each year. A key factor in the prevention of colorectal cancer is the integration of leading-edge technologies into gastroenterology practices to increase detection rates," said Dr. James Weber , a gastroenterologist and chief executive officer of the GI Alliance. "Detection of adenomas during colonoscopy is an important quality metric. The addition of AI can increase the quality of colonoscopies, potentially improving diagnosis and outcomes for colon cancer patients."

"Colonoscopies allow highly skilled gastroenterologists to identify polyps and lesions that might develop into cancer. With GI Genius we can tap into the potential of artificial intelligence approaches to increase detection rates. This important new development helps us in our mission to detect colon cancer early and to improve patient outcomes," said Michael Sapienza , chief executive officer of the Colorectal Cancer Alliance.

The GI Genius module uses advanced AI to highlight the presence of precancerous lesions with a visual marker in real-time – serving as an ever vigilant second observer. It processes images using advanced algorithms that can identify and mark abnormalities consistent with polyps, including small flat polyps that might otherwise go undetected by the human eye. Studies have shown that having a second observer can increase polyp detection rates and every 1% increase in adenoma detection rate (ADR) reduces the risk of colorectal cancer by 3%. 2,3 Use of the GI Genius module has demonstrated a 14% absolute increase in ADR compared to colonoscopy alone for both flat (42% increase) and polyploid (36% increase) lesions, thus increasing accuracy and reducing the rise of interval cancers which can occur between colonoscopies. 4

"Medtronic is committed to preventing colorectal cancer and improving patient outcomes with disruptive technologies that aid screening, increase patient compliance, and improve treatment," said Giovanni Di Napoli , president of the Gastrointestinal business, which is part of the Medical Surgical Portfolio at Medtronic. "With FDA de novo clearance for the GI Genius and its AI capabilities, we expect to enhance and improve colonoscopies and polyp detection. By introducing AI technology into the colonoscopy market, we anticipate improving colonoscopy detection rates and reducing variability in patient outcomes."

Medtronic is the exclusive worldwide distributor of the GI Genius module, which was developed and is manufactured by Cosmo Pharmaceuticals. The GI Genius intelligent endoscopy module received de novo clearance from the U.S. FDA on April 9, 2021 . In addition to the United States , the GI Genius module is available in Europe and select markets in Asia , Australia and the Middle East .

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

For detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events, please consult the device manual. For further information, contact your local Medtronic representative.

  1. Globocan. Estimated number of deaths in 2018 worldwide, both sexes, all ages. Globocan Cancer Data. Published 2018. Accessed Jan 2021 .
  2. Wang P, Berzin TM, Glissen Brown JR , et al. Gut 2019; 68:1813-1819.
  3. Corley DA, Jenson CD, Marks AR JR, et al. NEJM 2014;370:1298-306.
  4. Repici, A., Badalamenti, M., Maselli, R., et al. Gastroenterology 2020; doi: https://doi.org/10.1053/j.gastro.2020.04.062 .

Contacts:


John Jordan

Ryan Weispfenning

Public Relations

Investor Relations

+1-508-452-4891

+1-763-505-4626

The GI Genius™ intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/us-fda-grants-de-novo-clearance-for-first-and-only-artificial-intelligence-system-for-colonoscopy-medtronic-launches-gi-genius-intelligent-endoscopy-module-301266276.html

SOURCE Medtronic plc

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/12/c2450.html

News Provided by Canada Newswire via QuoteMedia

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022 .

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday , May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

  • Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
  • Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
  • One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU ® Research Posters Will Be Presented

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week® (DDW) 2022 which is being held virtually and in-person in San Diego, Calif. from May 21-24, 2022 . The posters will be accessible on DDW's ePoster's website beginning Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×